 |
Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells |
|---|---|
| Trade Name | |
| Orphan Indication | Primary central nervous system malignancies |
| USA Market Approval | USA |
| USA Designation Date | 2007-04-27 00:00:00 |
| Sponsor | TVAX Biomedical, LLC;8006 Reeder Street;Lenexa, Kansas, 66214 |
